BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the company’s third quarter ended September 30, 2011.
Third Quarter 2011 Highlights
•Revenue for the third quarter of 2011 increased by 321% to $395,000, compared to $94,000 for the same period in 2010.
